This article is more than 5 years old. Information may no longer be current.

FDA approves two Tecnis multifocal IOLs from Abbott

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food and Drug Administration approved Abbott’s +2.75 D and +3.25 D Tecnis one-piece multifocal IOLs, according to a press release.

The new IOLs provide cataract patients with options to have a full range of near, intermediate and distance vision, with a treatment customized to meet their personal needs and lifestyle, the release said.

The +3.25 D IOL is ideal for people performing activities at longer reading distances, such as reading a hand-held device. The +2.75 D IOL is ideal for people performing activities at intermediate distance, such as reading labels while shopping, according to Abbott.

The approval was based on a study of 445 cataract patients. More than 80% of patients functioned comfortably without glasses at all distances, and 93% of patients said they would have the same IOL implanted again. Mean uncorrected visual acuity was 20/25 in both eyes at near distances and 20/20 in both eyes at far distances, the release said.